PYCR1 and familial pancreatic carcinoma: Conversely, proline supplementation mitigated the effects of PYCR1 downregulation, partially rescuing the decrease in cell viability and suggesting a potential therapeutic strategy for counteracting the metabolic vulnerabilities of pancreatic cancer cells (Fig. 6).